



HealthLinx Limited

HealthLinx and InSymbiosis to co-develop therapeutic for lung disease

20 June 2008, Melbourne: HealthLinx Limited (ASX:HTX) and Canadian-based InSymbiosis Discovery Inc (InSymbiosis) have signed a Letter of Intent to co-develop HTX's peptide therapeutic CR014 and related compounds for applications in Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury. The companies will proceed under a joint venture agreement subject to the completion of due diligence.

ARDS is a complex syndrome affecting the vital functions of the lungs for which there are no effective therapeutic treatments available and 30-40% of patients who develop this syndrome will die. CR014 has demonstrated efficacy in reducing the adverse effects of lung injury in an animal model of ARDS. The proposed joint venture will conduct a full pre-clinical evaluation of CR014 with a view to progressing to clinical trials.

"The Joint Venture with InSymbiosis is a good opportunity for HTX to continue to extract value from its therapeutic assets while maintaining the company's primary focus and resource commitment to delivering new diagnostics. In particular, the upcoming release of HTX's new ovarian cancer diagnostic, OvPlex." said Greg Rice, Chairman of HealthLinx.

InSymbiosis, a Canadian company based in Montréal, Québec, is a leader in customised pre-clinical drug discovery and development services. The company's services spanning from early target and drug discovery through to IND for both small molecule and biologics drugs.

"InSymbiosis have developed strong capabilities in pre-clinical drug development to rapidly and cost effectively enable pre-clinical drug candidates to enter clinical trials. This joint venture with HealthLinx allows InSymbiosis to leverage its capabilities to continue to build a portfolio of collaborations with international biopharma companies which will solidify InSymbiosis' position as a leading collaborative drug development organization" said Dean Wenham, President and CEO of InSymbiosis.

"A successful outcome of the JV will position CR014 as a lead candidate for clinical evaluation in the treatment of not only ARDS but other related lung syndromes," Rice further stated.

CR014 is a compound that was licensed in from the University of Virginia in 2006 and has been further developed by the HealthLinx team. The compound is a novel natural human peptide that inhibits aberrant vascular permeability and associated inflammation after acute lung injury.

The HTX board has terminated the previously announced intention to spin off CR014 to Proaegis Limited.

Enquiries

Greg Rice (HealthLinx Limited) +61 3 9208 4200

Rudi Michelson (Monsoon Communications) +61 3 9620 3333

Dean Wenham (InSymbiosis) +1 514 807 9315

About HealthLinx Limited (ASX:HTX)

HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are:

- Ovarian cancer diagnostic (OvPlex) targeting US\$250m pa market; and
- Pregnancy diagnostic. This would be used in a woman's first prenatal visit to identify whether she is at high risk of having complications during pregnancy. Currently there is no product on the market which identifies complications in early stages of pregnancy.

A biomarker is a specific biochemical in the body that is used to measure progress of disease or the effects of treatment.

HealthLinx targets important markets with unmet needs. HealthLinx is developing product applications to successful Phase II biomarker trials and will then seek to out-license to partners for upfront and milestone payments and royalties on sales.

The company also has significant IP in Protein Depletion Technologies (ClearIT™) that depletes serum and other biological fluids of high abundant proteins. HealthLinx offers access to the Cryptomics Platform, which screens and identifies bio-active peptides for nutraceutical, functional foods and biological applications, on a fee for service and or collaborative basis

www.healthlinx.com.au

About InSymbiosis Discovery Inc. (InSymbiosis)

InSymbiosis is a pre-clinical drug discovery and development services company based in Montreal, Canada. InSymbiosis have developed a unique paradigm for drug development based around a lean virtual model which leverages high quality and cost effective Canadian research and development resources. Key to the success of the InSymbiosis model is the effective use of project and program management skills to allow for the effective planning and execution of pre-clinical programs. InSymbiosis is now extending its business model to enter into joint venture programs thereby allowing the Company to grow mid-long term revenue streams.

Information regarding InSymbiosis' services and business model can be found at www.insymbiosis.com